AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 30552272 — intervention group
Group type: COMPARATOR
Intervention: Standard DMP care
Number of subjects: 279
Study 26440470 — intervention group
Group type: EXPERIMENTAL
Intervention: Everolimus-eluting stent (EES)
Number of subjects: 22
Study 26440470 — intervention group
Group type: EXPERIMENTAL
Intervention: Biolimus A9-eluting stent (BES)
Number of subjects: 22
Study 26440470 — intervention group
Group type: COMPARATOR
Intervention: Control vessel
Number of subjects: 22
Study 23180285 — intervention group
Group type: EXPERIMENTAL
Intervention: 4-session mindfulness group intervention
Number of subjects: 114
Study 23180285 — intervention group
Group type: COMPARATOR
Intervention: Minimal mindfulness self-help control group
Number of subjects: 114
Study 23180285 — intervention group
Group type: EXPERIMENTAL
Intervention: 4-session mindfulness group intervention (for patients younger than 60 years)
Number of subjects: 114
Study 23180285 — intervention group
Group type: COMPARATOR
Intervention: Minimal mindfulness self-help control group (for patients younger than 60 years)
Number of subjects: 114
Study 22868684 — intervention group
Group type: EXPERIMENTAL
Intervention: Nalfurafine hydrochloride (5 µg/day)
Number of subjects: 211
Study 20358154 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous magnesium sulphate (MgSO4)
Number of subjects: 25
Study 20358154 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled nitric oxide (iNO)
Number of subjects: 25
Study 20358154 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled nitric oxide (iNO) after failed MgSO4 therapy
Number of subjects: 25
Study 20358154 — intervention group
Group type: COMPARATOR
Intervention: Intravenous magnesium sulphate (MgSO4) after failed iNO therapy
Number of subjects: 25
Study 18553228 — intervention group
Group type: EXPERIMENTAL
Intervention: S-1 and docetaxel combination (Treatment Arm A)
Number of subjects: 628
Study 18553228 — intervention group
Group type: COMPARATOR
Intervention: S-1 only (Treatment Arm B)
Number of subjects: 628
Study 16122471 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood cardioplegia
Number of subjects: 30
Study 16122471 — intervention group
Group type: COMPARATOR
Intervention: Crystalloid cardioplegia
Number of subjects: 30
Study 12423984 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitazoxanide (100 mg twice daily orally for 3 days)
Number of subjects: 100
Study 12423984 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 10712712 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.125% bupivacaine with ketamine 0.5 mg.kg‐1
Number of subjects: 40
Study 10712712 — intervention group
Group type: COMPARATOR
Intervention: 0.25% bupivacaine with ketamine 0.5 mg.kg‐1
Number of subjects: 40
Study 10712712 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 40
Study 8626113 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy alone (cisplatin and bleomycin)
Number of subjects: 89
Study 8626113 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy plus whole pelvic radiation therapy (RT)
Number of subjects: 89
Study 8626113 — intervention group
Group type: EXPERIMENTAL
Intervention: Both regimens (Chemotherapy alone and Chemotherapy plus RT)
Number of subjects: 89
Study 8626113 — intervention group
Group type: EXPERIMENTAL
Intervention: Both regimens
Number of subjects: 89
Study 1907963 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupropion (225-450 mg/day)
Number of subjects: 123
Study 1907963 — intervention group
Group type: COMPARATOR
Intervention: Fluoxetine (20-80 mg/day)
Number of subjects: 123
Study 1907963 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 123
Study 6626921 — intervention group
Group type: EXPERIMENTAL
Intervention: Return to full working duties 21 days after operation (Group A)
Number of subjects: 97
Study 6626921 — intervention group
Group type: EXPERIMENTAL
Intervention: Return to light duties 21 days after operation and to full duties at 3 months (Group B)
Number of subjects: 97
Study 6626921 — intervention group
Group type: COMPARATOR
Intervention: Return to work immediately (Group C)
Number of subjects: 97
Study 6626921 — intervention group
Group type: COMPARATOR
Intervention: No advice (Group D)
Number of subjects: 97
Study 31239200 — intervention group
Group type: EXPERIMENTAL
Intervention: Blephadex™ Eyelid Wipes (used on treated eyes once daily for 30 days)
Number of subjects: 20
Study 27807617 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral Nutritional Supplements (ONS) administered until 12 weeks after discharge
Number of subjects: 113
Study 27807617 — intervention group
Group type: COMPARATOR
Intervention: Usual postoperative diet (Control)
Number of subjects: 113
Study 26809652 — intervention group
Group type: EXPERIMENTAL
Intervention: Consolidation chemotherapy with oral vinorelbine (60-80 mg/m² days 1 and 8) + cisplatin (80 mg/m² day 1) q3w
Number of subjects: 201
Study 26809652 — intervention group
Group type: COMPARATOR
Intervention: Best supportive care (BSC) alone
Number of subjects: 201
Study 26809652 — intervention group
Group type: EXPERIMENTAL
Intervention: Consolidation chemotherapy with oral vinorelbine and cisplatin
Number of subjects: 201
Study 24745197 — intervention group
Group type: EXPERIMENTAL
Intervention: Aversive leadership
Number of subjects: 0
Study 24745197 — intervention group
Group type: EXPERIMENTAL
Intervention: Directive leadership
Number of subjects: 0
Study 24745197 — intervention group
Group type: EXPERIMENTAL
Intervention: Transactional leadership
Number of subjects: 0
Study 24745197 — intervention group
Group type: EXPERIMENTAL
Intervention: Person-focused leadership
Number of subjects: 0
Study 21091403 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline hearing loss prevention training, follow-up toolbox (TB) reinforcement trainings, and use of a personal noise level indicator (NLI)
Number of subjects: 176
Study 21091403 — intervention group
Group type: EXPERIMENTAL
Intervention: Toolbox (TB) reinforcement trainings and use of a personal noise level indicator (NLI)
Number of subjects: 176
Study 21091403 — intervention group
Group type: COMPARATOR
Intervention: Baseline training only
Number of subjects: 176
Study 19916203 — intervention group
Group type: EXPERIMENTAL
Intervention: Pegylated interferon alpha‐2b (1.5 microg/kg/week) and ribavirin (1000‐1200 mg/day orally)
Number of subjects: 110
Study 19916203 — intervention group
Group type: EXPERIMENTAL
Intervention: Pegylated interferon alpha‐2b and ribavirin
Number of subjects: 110
Study 19916203 — intervention group
Group type: COMPARATOR
Intervention: Interferon alpha‐2b (6 MIU, three times/week) and ribavirin
Number of subjects: 110
Study 19916203 — intervention group
Group type: COMPARATOR
Intervention: Interferon alpha‐2b and ribavirin
Number of subjects: 110
Study 17533961 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate dementia scenario
Number of subjects: 476
Study 17533961 — intervention group
Group type: EXPERIMENTAL
Intervention: Severe dementia scenario
Number of subjects: 476
Study 17533961 — intervention group
Group type: EXPERIMENTAL
Intervention: Community residents
Number of subjects: 476
Study 17533961 — intervention group
Group type: EXPERIMENTAL
Intervention: Care professionals
Number of subjects: 476
Study 15527186 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture treatment
Number of subjects: 300
Study 15527186 — intervention group
Group type: COMPARATOR
Intervention: No treatment, sham acupuncture, or standard treatment
Number of subjects: 300
Study 11602811 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciprofibrate (100 mg/d)
Number of subjects: 23
Study 11602811 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciprofibrate + Aspirin (100 mg/d)
Number of subjects: 23
Study 11602811 — intervention group
Group type: COMPARATOR
Intervention: Aspirin (100 mg/d)
Number of subjects: 23
Study 9838246 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth hormone (GH) replacement
Number of subjects: 1
Study 9838246 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1
Study 8076919 — intervention group
Group type: EXPERIMENTAL
Intervention: Sclerotherapy
Number of subjects: 253
Study 8076919 — intervention group
Group type: COMPARATOR
Intervention: Sham-therapy
Number of subjects: 253
Study 2739343 — intervention group
Group type: EXPERIMENTAL
Intervention: Mineral supplementation with 0.4 mmol calcium gluconate and 0.2 mmol glucose-1-phosphate/dl human milk
Number of subjects: 23
Study 2739343 — intervention group
Group type: COMPARATOR
Intervention: No mineral supplementation
Number of subjects: 23
Study 31392337 — intervention group
Group type: COMPARATOR
Intervention: 0.40 mg Cr/kg diet (2× the approved level)
Number of subjects: 216
Study 31392337 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.0 mg Cr/kg diet (10× the approved level)
Number of subjects: 216
Study 28481416 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood flow restricted exercise (BFR) at 100 mmHg, 20% 1RM to concentric failure (BFRE)
Number of subjects: 0
Study 28481416 — intervention group
Group type: COMPARATOR
Intervention: Low-load exercise (LLE)
Number of subjects: 0
Study 28481416 — intervention group
Group type: COMPARATOR
Intervention: High-load exercise (HLE) at 70% 1RM
Number of subjects: 0
Study 28481416 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood flow restricted exercise (BFR)
Number of subjects: 0
Study 26615448 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled epinephrine (4 mg/mL solution administered during mean 18 min)
Number of subjects: 9
Study 26615448 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular epinephrine (0.3 mg)
Number of subjects: 9
Study 26615448 — intervention group
Group type: COMPARATOR
Intervention: Inhaled placebo
Number of subjects: 9
Study 24344941 — intervention group
Group type: EXPERIMENTAL
Intervention: Sitagliptin 100 mg once daily for 12 weeks
Number of subjects: 28
Study 24344941 — intervention group
Group type: COMPARATOR
Intervention: Insulin glargine as add-on therapy (n=17)
Number of subjects: 28
Study 24344941 — intervention group
Group type: EXPERIMENTAL
Intervention: Sitagliptin
Number of subjects: 28
Study 21251993 — intervention group
Group type: EXPERIMENTAL
Intervention: ICS 400 group
Number of subjects: 96
Study 21251993 — intervention group
Group type: EXPERIMENTAL
Intervention: ICS 800 group
Number of subjects: 96
Study 21251993 — intervention group
Group type: EXPERIMENTAL
Intervention: ICS 800 with vit D group
Number of subjects: 96
Study 21251993 — intervention group
Group type: COMPARATOR
Intervention: Control group (montelukast)
Number of subjects: 96
Study 18425538 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mL 0.25% levobupivacaine and 40 mg methylprednisolone before wound closure
Number of subjects: 100
Study 18425538 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mL 0.25% levobupivacaine alone before closure
Number of subjects: 100
Study 18425538 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mL 0.25% levobupivacaine and 40 mg methylprednisolone before incision
Number of subjects: 100
Study 18425538 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mL 0.25% levobupivacaine alone before incision
Number of subjects: 100
Study 18425538 — intervention group
Group type: COMPARATOR
Intervention: 30 mL 0.9% NaCl before wound closure
Number of subjects: 100
Study 16528504 — intervention group
Group type: EXPERIMENTAL
Intervention: BrainLAB Kolibri navigation system
Number of subjects: 70
Study 16528504 — intervention group
Group type: COMPARATOR
Intervention: Conventional surgery
Number of subjects: 70
Study 12491025 — intervention group
Group type: EXPERIMENTAL
Intervention: Naltrexone (50 mg) + THC (30 mg)
Number of subjects: 39
Study 12491025 — intervention group
Group type: EXPERIMENTAL
Intervention: THC (0, 15, 30 mg) with active naltrexone (50 mg)
Number of subjects: 39
Study 12491025 — intervention group
Group type: COMPARATOR
Intervention: THC (0, 15, 30 mg) with placebo naltrexone
Number of subjects: 39
Study 12491025 — intervention group
Group type: COMPARATOR
Intervention: Methadone (5, 10 mg)
Number of subjects: 39
Study 11140433 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate (FP) - oral (5 to 40 mg), inhaled (500 to 2000 microg), intravenous (250 to 1000 g)
Number of subjects: 122
Study 11140433 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate (FP)
Number of subjects: 122
Study 8865055 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate-dose lidocaine (3 mg/kg)
Number of subjects: 283
Study 8865055 — intervention group
Group type: COMPARATOR
Intervention: Low-dose lidocaine (1.5 mg/kg)
Number of subjects: 283
Study 1531469 — intervention group
Group type: EXPERIMENTAL
Intervention: Intratubal injection of methotrexate (MTX)
Number of subjects: 0
Study 1531469 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study 7019761 — intervention group
Group type: EXPERIMENTAL
Intervention: Domperidone
Number of subjects: 0
Study 7019761 — intervention group
Group type: COMPARATOR
Intervention: Metoclopramide
Number of subjects: 0
Study 7019761 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 31078124 — intervention group
Group type: EXPERIMENTAL
Intervention: Dental pattern analysis system with treatment chronology on panoramic radiography
Number of subjects: 500
Study 27739188 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupropion (BUP; 4 × 150 mg)
Number of subjects: 9
Study 25858408 — intervention group
Group type: EXPERIMENTAL
Intervention: Watching cartoons during immunisation
Number of subjects: 35
Study 25858408 — intervention group
Group type: COMPARATOR
Intervention: Standard distraction techniques during immunisation
Number of subjects: 35
Study 23557110 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucose infusion (10% glucose, 2.5 mL/kg/h)
Number of subjects: 11
Study 23557110 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucose-insulin infusion (10% glucose added 30 IU NovoRapid® per litre, 2.5 mL/kg/h)
Number of subjects: 11
Study 23557110 — intervention group
Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 11
Study 23557110 — intervention group
Group type: EXPERIMENTAL
Intervention: All interventions
Number of subjects: 11
Study 21427153 — intervention group
Group type: EXPERIMENTAL
Intervention: Gait trainer assisted walking exercises
Number of subjects: 30
Study 21427153 — intervention group
Group type: COMPARATOR
Intervention: Traditional physical therapy
Number of subjects: 30
Study 21427153 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 30
Study 19070855 — intervention group
Group type: EXPERIMENTAL
Intervention: Medication management training for CMHPs
Number of subjects: 95
Study 19070855 — intervention group
Group type: COMPARATOR
Intervention: Waiting list control
Number of subjects: 95
Study 17390690 — intervention group
Group type: EXPERIMENTAL
Intervention: Haloperidol (10 microg x kg(-1))
Number of subjects: 75
Study 17390690 — intervention group
Group type: EXPERIMENTAL
Intervention: Droperidol (10 microg x kg(-1))
Number of subjects: 75
Study 17390690 — intervention group
Group type: COMPARATOR
Intervention: Physiologic saline solution (Control)
Number of subjects: 75
Study 14993509 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraperitoneal tinzaparin (low‐molecular weight heparin) administered once a day for 3 months
Number of subjects: 21
Study 14993509 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study 11888531 — intervention group
Group type: COMPARATOR
Intervention: Diet protocol (20 kcal per kg fat‐free mass (FFM); 55% carbohydrates, 30% fat, and 15% proteins)
Number of subjects: 79
Study 11888531 — intervention group
Group type: EXPERIMENTAL
Intervention: Malabsorptive surgery (biliopancreatic diversion)
Number of subjects: 79
Study 11888531 — intervention group
Group type: COMPARATOR
Intervention: Diet protocol
Number of subjects: 79
Study 11888531 — intervention group
Group type: EXPERIMENTAL
Intervention: Malabsorptive surgery
Number of subjects: 79
Study 11888531 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet protocol and Malabsorptive surgery
Number of subjects: 79
Study 9650015 — intervention group
Group type: EXPERIMENTAL
Intervention: Soybean oil meal
Number of subjects: 10
Study 9650015 — intervention group
Group type: COMPARATOR
Intervention: Mixed meal
Number of subjects: 10
Study 9650015 — intervention group
Group type: COMPARATOR
Intervention: Cream meal
Number of subjects: 10
Study 8587293 — intervention group
Group type: COMPARATOR
Intervention: 2 g MMF daily
Number of subjects: 0
Study 8587293 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 g MMF daily
Number of subjects: 0
Study 8587293 — intervention group
Group type: COMPARATOR
Intervention: Standard regimen of cyclosporine and prednisone
Number of subjects: 0
Study 2568816 — intervention group
Group type: EXPERIMENTAL
Intervention: High-osmolar contrast media (meglumine diatrizoate 76, 2100 mOsm/kg)
Number of subjects: 40
Study 2568816 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-osmolar contrast media (iopamidol 370, 832 mOsm/kg)
Number of subjects: 40
Study 2568816 — intervention group
Group type: COMPARATOR
Intervention: Control period (baseline measurements before CM injection)
Number of subjects: 40
Study 579125 — intervention group
Group type: EXPERIMENTAL
Intervention: Etofenamate (Rheumon Gel)
Number of subjects: 0
Study 579125 — intervention group
Group type: COMPARATOR
Intervention: Placebo gel
Number of subjects: 0
Study 31391001 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (1 μ/kg over 10 min, pre-operatively)
Number of subjects: 90
Study 31391001 — intervention group
Group type: COMPARATOR
Intervention: Control (0.9% saline infusion)
Number of subjects: 90
Study 28187952 — intervention group
Group type: EXPERIMENTAL
Intervention: AS03-adjuvanted H7N1 vaccine (3.75 or 7.5μg hemagglutinin with AS03A or AS03B)
Number of subjects: 420
Study 28187952 — intervention group
Group type: EXPERIMENTAL
Intervention: Unadjuvanted H7N1 vaccine (15μg hemagglutinin)
Number of subjects: 420
Study 28187952 — intervention group
Group type: COMPARATOR
Intervention: Saline placebo
Number of subjects: 420
Study 28187952 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvanted groups
Number of subjects: 420
Study 25628308 — intervention group
Group type: EXPERIMENTAL
Intervention: Heart failure with preserved ejection fraction
Number of subjects: 3487
Study 25628308 — intervention group
Group type: COMPARATOR
Intervention: Heart failure with reduced ejection fraction
Number of subjects: 3487
Study 25628308 — intervention group
Group type: COMPARATOR
Intervention: Degree of left ventricular systolic dysfunction (LVSD)
Number of subjects: 3487
Study 25628308 — intervention group
Group type: COMPARATOR
Intervention: New York Heart Association class
Number of subjects: 3487
Study 23324131 — intervention group
Group type: EXPERIMENTAL
Intervention: pemetrexed 500 mg/m² + cisplatin 75 mg/m² IV every 21 days × 3 cycles, followed by surgery and hemithoracic radiation (54 Gy)
Number of subjects: 54
Study 23324131 — intervention group
Group type: EXPERIMENTAL
Intervention: pemetrexed plus cisplatin followed by surgery and hemithoracic radiation (50.4 Gy after protocol amendment)
Number of subjects: 54
Study 21677899 — intervention group
Group type: EXPERIMENTAL
Intervention: GEn 1200 mg
Number of subjects: 325
Study 21677899 — intervention group
Group type: EXPERIMENTAL
Intervention: GEn 600 mg
Number of subjects: 325
Study 21677899 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 325
Study 19353317 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic Condylar Screw (DCS)
Number of subjects: 68
Study 19353317 — intervention group
Group type: COMPARATOR
Intervention: Retrograde Intramedullary Supracondylar Nail (RIMSN)
Number of subjects: 68
Study 17803667 — intervention group
Group type: EXPERIMENTAL
Intervention: ORS with probiotic powder containing 60 million cells of Lactobacillus rhamnosus GG (LGG)
Number of subjects: 646
Study 17803667 — intervention group
Group type: COMPARATOR
Intervention: ORS alone
Number of subjects: 646
Study 15148493 — intervention group
Group type: EXPERIMENTAL
Intervention: Granulocyte colony-stimulating factor (G‐CSF)
Number of subjects: 72
Study 15148493 — intervention group
Group type: COMPARATOR
Intervention: Granulocyte-macrophage colony-stimulating factor (GM‐CSF)
Number of subjects: 72
Study 15148493 — intervention group
Group type: EXPERIMENTAL
Intervention: Both G‐CSF and GM‐CSF
Number of subjects: 72
Study 12200890 — intervention group
Group type: EXPERIMENTAL
Intervention: High-frequency oscillatory ventilation (HFOV)
Number of subjects: 0
Study 12200890 — intervention group
Group type: COMPARATOR
Intervention: Conventional ventilation (CV)
Number of subjects: 0
Study 9830189 — intervention group
Group type: EXPERIMENTAL
Intervention: Alternative benzodiazepine
Number of subjects: 0
Study 9830189 — intervention group
Group type: EXPERIMENTAL
Intervention: Antihistamines as substitute hypnotics
Number of subjects: 0
Study 7924173 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine (250 mg)
Number of subjects: 9
Study 7924173 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study 2528926 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.0 micrograms/kg sufentanil
Number of subjects: 62
Study 2528926 — intervention group
Group type: COMPARATOR
Intervention: 0.5 micrograms/kg sufentanil
Number of subjects: 62
Study 2528926 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.5 micrograms/kg sufentanil
Number of subjects: 62
Study 838241 — intervention group
Group type: EXPERIMENTAL
Intervention: Droperidol
Number of subjects: 0
Study 838241 — intervention group
Group type: COMPARATOR
Intervention: Diazepam
Number of subjects: 0
Study 30876450 — intervention group
Group type: EXPERIMENTAL
Intervention: Flexible video endoscope
Number of subjects: 174
Study 30876450 — intervention group
Group type: COMPARATOR
Intervention: Macintosh laryngoscope
Number of subjects: 174
Study 29357033 — intervention group
Group type: EXPERIMENTAL
Intervention: Resveratrol 800 mg/day for 2 months
Number of subjects: 48
Study 29357033 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study 26978782 — intervention group
Group type: EXPERIMENTAL
Intervention: Progressive inspiratory threshold loading
Number of subjects: 28
Study 26978782 — intervention group
Group type: COMPARATOR
Intervention: Control (not explicitly mentioned)
Number of subjects: 28
Study 25017249 — intervention group
Group type: EXPERIMENTAL
Intervention: Prostate cancer dietary index score
Number of subjects: 13011
Study 25017249 — intervention group
Group type: EXPERIMENTAL
Intervention: Adherence to recommendations to increase plant foods
Number of subjects: 13011
Study 25017249 — intervention group
Group type: EXPERIMENTAL
Intervention: Adherence to tomato products
Number of subjects: 13011
Study 25017249 — intervention group
Group type: EXPERIMENTAL
Intervention: WCRF/AICR index score
Number of subjects: 13011
Study 23091850 — intervention group
Group type: EXPERIMENTAL
Intervention: Perindopril
Number of subjects: 30
Study 23091850 — intervention group
Group type: COMPARATOR
Intervention: Enalapril
Number of subjects: 30